Skip to main content

Table 1 Meta-analysis results of oncology trials that examined erythopoietin’s affect on disease progression in patients receiving chemotherapy

From: Erythropoietin is a JAK2 and ERK1/2 effector that can promote renal tumor cell proliferation under hypoxic conditions

Study publication

Tumor type

No. of patients analyzed

Odds ratio (95%) for disease progression

Osterborg et al. 1996[34]

Hematologic

144

1.20 (0.60-2.40)

Littlewood et al. 2001[35]

Solid (non-hematologic)

375

0.64 (0.40-1.02)

Pronzato et al. 2010[36]

Breast

223

1.02 (0.46-2.26)

Vansteenkiste et al. 2002[37]

SCLC and NSCLC

314

0.58 (0.30-1.11)

Hedenus et al. 2003[38]

Hematologic

344

1.08 (0.66-1.76)

Vadhan-Raj et al. 2003[39]

Gastric and rectal

60

1.01 (0.35-2.94)

Chang et al. 2005[40]

Breast

354

0.82 (0.39-1.72)

Grote et al. 2005[41]

SCLC

224

0.85 (0.50-1.44)

Leyland-Jones et al. 2005[42]

Breast

939

0.84 (0.64-1.08)

Osterborg et al. 2005[43]

Hematologic

343

0.74 (0.44-1.25)

Witzig et al. 2005[44]

Mixed

344

1.20 (0.75-1.91)

Wilkinson et al. 2006[11]

Ovarian

181

7.47 (0.95-58.54)

Engert et al. 2007[45]

Hodgkin’s lymphoma

1303

0.86 (0.33-2.24)

Aapro et al. 2008[46]

Breast

463

1.07 (0.82-1.40)

Pirker et al. 2008[47]

SCLC

596

0.87 (0.52-1.46)

Strauss et al. 2008[48]

Cervical

74

0.87 (0.32-2.33)

Thomas et al. 2008[49]

Cervical

109

1.02 (0.48-2.15)